Evusheld (tixagevimab/cilgavimab), the coronavirus antibody therapy developed by AstraZeneca (LSE: AZN), has been approved in the UK.
AstraZeneca has already secured US authorization for the long-acting antibody combination, with the US government subsequently ordering additional supplies, for a total of 1.7 million doses, at a value of around a billion dollars.
Unlike rival antibody therapies developed by GlaxoSmithKline (LSE: GSK), Eli Lilly (NYSE: LLY) and Regeneron (Nasdaq: REGN), AstraZeneca’s option is approved for pre-exposure prophylaxis (PrEP), a key differentating factor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze